1. Home
  2. BDSX vs HURA Comparison

BDSX vs HURA Comparison

Compare BDSX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$28.50

Market Cap

276.2M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.09

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
HURA
Founded
2005
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.2M
160.5M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
BDSX
HURA
Price
$28.50
$2.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$32.50
$9.50
AVG Volume (30 Days)
88.8K
162.8K
Earning Date
05-04-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.93
EPS
N/A
N/A
Revenue
$88,499,000.00
N/A
Revenue This Year
$25.26
N/A
Revenue Next Year
$19.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$5.26
$0.41
52 Week High
$31.31
$3.43

Technical Indicators

Market Signals
Indicator
BDSX
HURA
Relative Strength Index (RSI) 58.15 48.97
Support Level $19.26 $2.04
Resistance Level $31.31 $2.24
Average True Range (ATR) 1.64 0.09
MACD 0.03 0.01
Stochastic Oscillator 71.96 57.50

Price Performance

Historical Comparison
BDSX
HURA

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: